Header Logo

Connection

JULIE NANGIA to Capecitabine

Back to Details
This is a "connection" page, showing publications JULIE NANGIA has written about Capecitabine.
JULIE NANGIA
Connection Strength
0.041
Capecitabine
  1. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.